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OBJECTIVE—To examine associations of neonatal adiposity
with maternal glucose levels and cord serum C-peptide in a
multicenter multinational study, the Hyperglycemia and Adverse
Pregnancy Outcome (HAPO) Study, thereby assessing the Ped-
erson hypothesis linking maternal glycemia and fetal hyperinsu-
linemia to neonatal adiposity.
RESEARCH DESIGN AND METHODS—Eligible pregnant
women underwent a standard 75-g oral glucose tolerance test
between 24 and 32 weeks gestation (as close to 28 weeks as
possible). Neonatal anthropometrics and cord serum C-peptide
were measured. Associations of maternal glucose and cord
serum C-peptide with neonatal adiposity (sum of skin folds
90th percentile or percent body fat 90th percentile) were
assessed using multiple logistic regression analyses, with adjust-
ment for potential confounders, including maternal age, parity,
BMI, mean arterial pressure, height, gestational age at delivery,
and the baby’s sex.
RESULTS—Among 23,316 HAPO Study participants with glu-
cose levels blinded to caregivers, cord serum C-peptide results
were available for 19,885 babies and skin fold measurements for
19,389. For measures of neonatal adiposity, there were strong
statistically signiﬁcant gradients across increasing levels of ma-
ternal glucose and cord serum C-peptide, which persisted after
adjustment for potential confounders. In fully adjusted continu-
ous variable models, odds ratios ranged from 1.35 to 1.44 for the
two measures of adiposity for fasting, 1-h, and 2-h plasma
glucose higher by 1 SD.
CONCLUSIONS—These ﬁndings conﬁrm the link between ma-
ternal glucose and neonatal adiposity and suggest that the
relationship is mediated by fetal insulin production and that the
Pedersen hypothesis describes a basic biological relationship
inﬂuencing fetal growth. Diabetes 58:453–459, 2009
T
he objective of the Hyperglycemia and Adverse
Pregnancy Outcome (HAPO) Study was to clar-
ify the risk of adverse outcome associated with
degrees of glucose intolerance during pregnancy
that are less severe than overt diabetes. Glucose tolerance
was measured by a 75-g 2-h oral glucose tolerance test
(OGTT) in a large, heterogeneous, multinational, ethni-
cally diverse cohort of women at 24–32 (mean 28) weeks
gestation with medical caregivers blinded to status of glucose
tolerance (except when predeﬁned thresholds were met) (1).
Associations between maternal glycemia and increased size
at birth, delivery by cesarean section, development of neo-
natal hypoglycemia, and the presence of fetal hyperinsulin-
emia were the predeﬁned primary outcomes of the study.
Results of the study showing continuous relationships of
maternal glucose levels below those diagnostic of diabetes
with each of the primary outcomes have been reported (2).
Associations of maternal glucose and birth weight 90th
percentile and fetal hyperinsulinemia [cord C-peptide con-
centration greater than the HAPO Study 90th percentile (1.7
g/l)] were strong. Weaker associations were found with
cesarean delivery and clinical neonatal hypoglycemia (2).
In 1952, Pedersen (3) postulated that maternal hypergly-
cemia was transmitted to the fetus, which, in turn, pro-
duced and released large amounts of insulin, with the
resultant fetal hyperinsulinemia being the cause of various
aspects of diabetic fetopathy, including deposition of large
amounts of body fat, which gave the infant its character-
istic appearance. Pedersen documented increased body
weight in infants of diabetic mothers compared with
control subjects. Fetal hyperinsulinemia, in the absence of
maternal diabetes, has been demonstrated to cause
“diabetes-like” fetopathy in rhesus monkey offspring (4).
At least some of the increased fetal weight has been shown
to be attributable to increased fat accretion (5).
In 1977, Whitelaw (6) reported an association between
diabetic control and skin fold thickness in infants of diabetic
mothers. Sparks reported that body fat more speciﬁcally
represents effects of the in utero environment, whereas lean
body mass represents more of the genetic component of
growth (7). For example, male neonates have greater birth
weight than females primarily because of increases in lean
body mass (8). Therefore, we elected to estimate body
composition, in particular fat mass and percent body fat, as
speciﬁc outcomes in the HAPO Study cohort.
These reports and many others validate the basic tenets
of the Pedersen hypothesis. However, efforts to deﬁne the
strength of associations with hyperglycemia are con-
founded by treatment. Furthermore, the direct link be-
tween maternal glycemia, fetal insulin response, and
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DIABETES, VOL. 58, FEBRUARY 2009 453neonatal body composition has not yet been demonstrated
in the subdiabetic glucose range. Goals of this report are
1) to examine associations of maternal glycemia with
newborn anthropometrics (skin folds, percent body fat);
and 2) to present data linking fetal hyperinsulinemia
(assessed by cord serum C-peptide) to the development of
larger and more obese babies.
RESEARCH DESIGN AND METHODS
The protocol was approved by the institutional review board at all 15 ﬁeld
centers. All participants gave written informed consent. An external data
monitoring committee provided oversight. Study methods have been pub-
lished previously (1,2,9). A brief overview is presented here.
All pregnant women at each ﬁeld center were eligible to participate unless
they had one or more exclusion criteria (2): age 18 years, delivery planned
at another hospital, date of last menstrual period (LMP) not certain and no
ultrasound estimation from 6–24 weeks of gestational age available, unable to
complete the OGTT by 32 weeks gestation, multiple pregnancy, conception
using gonadotropin ovulation induction or by in vitro fertilization, glucose
testing before recruitment or a diagnosis of diabetes during this pregnancy,
diabetes antedating pregnancy requiring treatment with medication, partici-
pation in another study that may interfere with HAPO, known to be HIV
positive or to have hepatitis B or C, prior participation in HAPO, or inability
to converse in the languages used in ﬁeld center forms without the aid of an
interpreter. If glucose measurements were made outside of HAPO after initial
enrollment, the participant was excluded from further participation.
Gestational age and expected date of delivery (EDD) were determined
from the date of the LMP, if the participant was certain of her dates. If
uncertain, EDD was determined from an ultrasound performed between 6 and
24 weeks gestation. Final EDD was also determined from ultrasound if 1)
gestational dating from LMP differed from ultrasound dating by 5 days, when
the ultrasound was performed between 6 and 13 weeks, or 2) if dating differed
by 10 days when the ultrasound was done between 14 and 24 weeks.
OGTT. Participants underwent a standard 75-g OGTT between 24 and 32
weeks gestation (as close to 28 weeks as possible). Height, weight, and blood
pressure were measured at the OGTT visit using standardized procedures and
calibrated equipment. Data concerning smoking and alcohol use, ﬁrst-degree
family history of diabetes, and demographic data were collected using
standardized questionnaires. Race/ethnicity was self-identiﬁed by partici-
pants. A sample for random plasma glucose (RPG) was collected at 34–37
weeks gestation as a safety measure to identify cases with hyperglycemia
above a predeﬁned threshold.
Glucose analysis and unblinding. Aliquots of fasting and 2-h OGTT and
RPG samples were analyzed at ﬁeld center laboratories. Values were un-
blinded if fasting plasma glucose (FPG) exceeded 5.8 mmol/l, if 2-h OGTT
plasma glucose exceeded 11.1 mmol/l, if RPG was 8.9 mmol/l, or if any
plasma glucose value was 2.5 mmol/l. Otherwise, women, caregivers, and
HAPO Study staff (except for laboratory personnel) remained blinded to
glucose values. To avoid confounding effects of center to center analytical
variation, aliquots of all OGTT specimens were analyzed at the HAPO Central
Laboratory, and these results are used here. Only women whose results
remained blinded, with no additional glucose testing outside the HAPO
protocol, are included in these analyses.
Cord serum C-peptide sample. Cord blood was collected at delivery, and
serum was analyzed for C-peptide on an Autodelﬁa instrument at the Central
Laboratory (9). Cord serum C-peptide (secreted in equimolar concentrations
with insulin) was used as the index of fetal -cell function rather than insulin
because insulin degradation is increased in the presence of even small
amounts of hemolysis, which occurs in 15% of cord samples, and because
C-peptide concentration is not altered by hemolysis (10). Functional sensitiv-
ity of the assay was 0.2 g/l (9).
Prenatal care and delivery. Prenatal care and timing of delivery were
determined by standard ﬁeld center practice. No ﬁeld center arbitrarily
delivered patients before full term or routinely performed cesarean delivery at
a speciﬁed maternal or gestational age.
Neonatal care and anthropometrics. After delivery, infants received cus-
tomary routine care. Medical records were abstracted to obtain data regarding
prenatal, labor and delivery, postpartum, and newborn course.
Neonatal anthropometrics were obtained within 72 h of delivery. To ensure
accuracy and reliability of anthropometric data and consistency across ﬁeld
centers, a rigorous training and certiﬁcation procedure was established for
study research nurses and midwives. Personnel were trained during regional
training sessions run by Clinical and Data Coordinating Center staff. A training
videotape providing instruction in anthropometric measurements was viewed.
Research personnel observed measurements and then performed measure-
ments on ﬁve infants. After training and before recruitment, research person-
nel continued to perform measurements locally on two infants per week and
demonstrated their proﬁciency with measuring neonatal anthropometrics
during a dry-run site visit. To maintain quality control of skin fold measures,
all research personnel underwent annual recertiﬁcation, which included
reviewing the videotape and providing data in tandem with another certiﬁed
individual on three to ﬁve babies.
Anthropometric measurements included weight, length, head circumfer-
ence, and skin fold thickness at three sites (ﬂank, subscapular, and triceps).
Two measurements were made, and if results differed by more than a
prespeciﬁed amount (10 g for weight, 0.5 cm for length and head
circumference, or 0.5 mm for skin folds, respectively), a third was done. For
these analyses, the average of the two measurements was used, unless a third
measurement was taken. In that case, if two of three measurements differed
by less than the prespeciﬁed amount, the average of those two was used;
otherwise the average of all three was used.
Birth weight was obtained without diaper using a calibrated electronic
scale. Length was measured on a standardized plastic length board con-
structed for use in the HAPO Study. Head circumference was measured across
the occipital fontanel (standard plastic measuring tape). Skin fold thickness
was measured with skin fold calipers (Harpenden, Baty, U.K.). Flank skin fold
was measured on the left side just above the iliac crest on a diagonal fold on
the mid axillary line, triceps by taking the vertical fold over the triceps muscle
half the distance between the acromion process and olecranon, and subscap-
ular just below the lower angle of the scapula at 45
o angle to the spine.
Mean coefﬁcients of variation for anthropometric measurements were:
birth weight 0.04%, length 0.17%, head circumference 0.16%, ﬂank skin fold
2.91%, subscapular skin fold 2.57%, and triceps skin fold 2.73%.
Outcomes
Sum of skin folds >90th percentile. For gestational age (36–44 weeks
only), 90th percentiles were determined using eight newborn gender-ethnic
groups (Caucasian or other, Black, Hispanic, or Asian), with adjustment for
gestational age, ﬁeld center, and parity (0, 1, and 2). A newborn was
TABLE 1
Characteristics of HAPO participants*
Maternal characteristics
Age (years) 19,885 (29.2  5.8)
Education (years) 18,223 (12.9  3.4)
Pre-pregnant BMI 18,200 (23.8  5.0)
BMI (kg/m
2)† 19,885 (27.5  5.0)
MAP (mmHg)† 19,885 (80.7  8.2)
FPG (mmol/l)† 19,885 (4.5  0.4)
1-h Plasma glucose (mmol/l)† 19,885 (7.5  1.7)
2-h Plasma glucose (mmol/l)† 19,885 (6.2  1.3)
Gestational age (weeks)† 19,885 (27.8  1.8)
Ethnicity
White, non-Hispanic 9,189 (46.2)
Black, non-Hispanic 2,279 (11.5)
Hispanic 1,774 (8.9)
Asian 6,181 (31.1)
Other 462 (2.3)
Prenatal smoking (any) 1,217 (6.1)
Prenatal alcohol use (any) 1,272 (6.4)
Family history of diabetes 4,411 (22.2)
Parity (prior delivery 20 weeks) 10,408 (52.3)
Newborn characteristics
Gestational age (weeks) 19,885 (39.4  1.6)
Birth weight (g) 19,884 (3,308  505)
Length (cm) 19,496 (49.8  2.4)
Head circumference (cm) 19,723 (34.2  1.5)
Flank skin fold (mm)‡ 17,159 (3.9  1.0)
Triceps skin fold (mm)‡ 17,136 (4.1  0.9)
Subscapular skin fold (mm)‡ 17,115 (4.2  1.0)
Sum of skin folds (mm)‡ 17,100 (12.3  2.6)
Body fat (%)‡ 17,050 (11.3  3.7)
Cord serum C-peptide (g/l) 19,885 (1.0  0.6)
Male 10,235 (51.5)
Data are n (mean  SD) or n (%). *Participants with a cord serum
C-peptide measurement. †Measured at the OGTT. ‡Babies with
gestational age 36–44 weeks at birth.
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than the estimated 90th percentile for the baby’s sex, gestational age,
ethnicity, ﬁeld center, and maternal parity. Otherwise, the newborn was
considered to have a sum 90th percentile.
Individual skin fold (ﬂank, triceps, and subscapular) >90th percen-
tile. An individual skin fold 90th percentile was deﬁned using the same
methods as for sum of skin folds 90th percentile.
Percent body fat >90th percentile. Fat mass was calculated from birth
weight, length, and ﬂank skin fold according to the equation given by Catalano
et al. (11) that was based on measurements of total body electrical conduc-
tivity (TOBEC). The derived formula was also prospectively validated with
estimates of fat mass by TOBEC. Percent body fat was then calculated as
100  fat mass/birth weight. Percent body fat 90th percentile was deﬁned
using the same methods as for sum of skin folds 90th percentile.
Birth weight >90th percentile. Birth weight 90th percentile was also
deﬁned using the same methods as for sum of skin folds 90th percentile,
with gestational ages of 30–44 weeks included.
Statistical analyses. Descriptive statistics include means and SDs for contin-
uous variables and numbers and percentages for categorical variables. For
analyses of associations of glycemia and cord serum C-peptide with fetal
adiposity (sum of skin folds 90th percentile or percent body fat 90th
percentile), each glucose measurement and cord C-peptide were considered as
both categorical and continuous variables in multiple logistic regression analyses.
For individual skin folds, only continuous variable results are presented. In
categorical analyses, each measure of glycemia was divided into seven categories
with 50% of all values in the two lowest categories and 3 and 1% in the two
highest categories, respectively (2). To make categorical analyses of outcomes
with cord C-peptide comparable with those for maternal glycemia, we also
divided cord C-peptide into seven categories so that 50% of values were in the
two lowest categories and 3 and 1% were in the two highest categories,
respectively. For glucose as a continuous variable, odds ratios (ORs) were
calculated for each measure (fasting, 1-, and 2-h plasma glucose) higher by 1 SD.
To assess whether the log of the odds of fetal adiposity was linearly related to
glucose, we added squared terms in each glucose measure. We also tested for
interactions of glucose with ﬁeld center, BMI, age, height, and mean arterial
pressure (MAP) for each glucose measure for each outcome. Because of the large
sample size in HAPO and the generally large number of women with each
outcome, squared terms as well as interaction terms were considered statistically
signiﬁcant only for P  0.001. We also examined cord C-peptide as a continuous
variable with both linear and squared terms for each outcome. However, because
the squared term was signiﬁcant (P0.001) for each outcome and the categorical
analysis appeared to provide a better ﬁt to the data, only the categorical analyses
are reported here for cord C-peptide.
For each outcome, two logistic models (I and II) were ﬁt, with model I
including adjustment for the variables used to deﬁne the 90th percentile for the
neonatal anthropometric measures and model II including additional adjustment
for multiple potential confounders that had been prespeciﬁed. Potential con-
founders included in model II were maternal age, BMI, height, gestational age,
and MAP at the OGTT; family history of diabetes; hospitalization before delivery;
smoking status; and alcohol use. Squared terms for age, BMI, and MAP were
prescreened for possible inclusion in model II adjustment in models that included
only linear and squared terms for these variables. Squared terms were included if
P  0.001. All analyses were conducted in SAS version 9.1 or Stata 10.0.
RESULTS
A cord C-peptide result was available for 19,885 babies of
the 23,316 blinded HAPO Study participants who were
included in the ﬁrst report of HAPO Study results (2).
Results shown in Table 1 are from those 19,885 babies and
their mothers. Mean maternal BMI at the OGTT was 27.5,
and the correlation with prepregnant BMI, which was
based on self-reported prepregnant weight, is 0.92. Mean
glucose levels among this group were 4.5, 7.5, and 6.2
mmol/l for fasting, 1-h, and 2-h plasma glucose, respec-
tively. Mean gestational age at delivery was 39.4 weeks,
TABLE 2
Relationship between maternal glucose and sum of skin folds 90th percentile*
n 90th percentile† Model I Model II
FPG (mmol/l)
4.2 3,340 177 (5.3) 1.00 1.00
4.2–4.4 6,270 480 (7.7) 1.48 (1.24–1.77) 1.39 (1.16–1.66)
4.5–4.7 5,186 504 (9.7) 1.92 (1.61–2.30) 1.66 (1.38–1.99)
4.8–4.9 2,287 278 (12.2) 2.47 (2.03–3.01) 2.00 (1.64–2.45)
5.0–5.2 1,556 259 (16.6) 3.57 (2.92–4.37) 2.72 (2.20–3.36)
5.3–5.5 576 119 (20.7) 4.65 (3.62–5.99) 3.37 (2.59–4.38)
5.6 174 46 (26.4) 6.42 (4.44–9.29) 4.71 (3.22–6.89)
Continuous‡ 19,389 1,863 (9.6) 1.52 (1.45–1.59) 1.39 (1.33–1.47)
1-h Plasma glucose (mmol/l)
5.8 3,482 212 (6.1) 1.00 1.00
5.9–7.3 6,258 483 (7.7) 1.29 (1.09–1.52) 1.22 (1.03–1.45)
7.4–8.6 5,007 468 (9.3) 1.59 (1.34–1.88) 1.50 (1.26–1.78)
8.7–9.5 2,324 310 (13.3) 2.37 (1.98–2.85) 2.22 (1.84–2.69)
9.6–10.7 1,570 245 (15.6) 2.85 (2.35–3.46) 2.63 (2.14–3.22)
10.8–11.7 536 103 (19.2) 3.67 (2.84–4.74) 3.38 (2.59–4.41)
11.8 212 42 (19.8) 3.81 (2.64–5.49) 3.57 (2.46–5.20)
Continuous‡ 19,389 1,863 (9.6) 1.44 (1.37–1.51) 1.42 (1.35–1.49)
2-h Plasma glucose (mmol/l)
5.0 3,537 209 (5.9) 1.00 1.00
5.1–6.0 6,135 496 (8.1) 1.40 (1.18–1.66) 1.32 (1.11–1.56)
6.1–6.9 4,948 481 (9.7) 1.71 (1.45–2.03) 1.60 (1.35–1.90)
7.0–7.7 2,556 352 (13.8) 2.54 (2.13–3.04) 2.38 (1.98–2.86)
7.8–8.7 1,444 198 (13.7) 2.53 (2.06–3.11) 2.39 (1.93–2.95)
8.8–9.8 576 90 (15.6) 2.95 (2.26–3.84) 2.80 (2.13–3.69)
9.9 193 37 (19.2) 3.78 (2.57–5.55) 3.59 (2.42–5.33)
Continuous‡ 19,389 1,863 (9.6) 1.37 (1.31–1.44) 1.36 (1.30–1.43)
Data are n (%) or OR (95% CI). n 	 total number in the glucose category (excluding births with gestational age 30 weeks and fetal deaths).
Model I, adjusted for the variables used in estimating 90th percentiles; model II, adjusted for age, BMI, BMI
2, height, mean arterial blood
pressure, gestational age at the OGTT, smoking, alcohol use, hospitalization prior to delivery, and any family history of diabetes. *Deﬁned
based on sex, ethnicity, ﬁeld center, gestational age (36–44 weeks), and parity. †Number in the glucose category with the sum of skin folds
90th percentile (% proportion in the glucose category with sum of skin folds 90th percentile). ‡Glucose higher by 1 SD (0.4 mmol/l for
FPG, 1.7 mmol/l for 1-h plasma glucose, 1.3 mmol/l for 2-h plasma glucose).
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ments were available for 19,389 babies overall and for
17,100 babies with a cord C-peptide result.
Tables 2 and 3 show associations of maternal glucose
with sum of skin folds 90th percentile and percent body
fat 90th percentile, including ORs and 95% CIs for each
category compared with the lowest or referent category.
Overall, 1,863 (9.6%) babies had a sum of skin folds 90th
percentile and 9.8% a percent body fat 90th percentile.
With higher levels of maternal fasting, 1-, and 2-h plasma
glucose concentrations, the proportion of babies with sum
of skin folds or percent body fat 90th percentile rose, for
example from 5.3 to 26.4% across FPG categories for sum
of skin folds and from 6.2 to 27.7% for percent body fat. In
model I, the OR was 6.42 in the highest category of FPG for
sum of skin folds and 5.77 for percent body fat. For sum of
skin folds, there was modest attenuation of the ORs with
adjustment for model II confounders for all three glucose
measures. For percent body fat 90th percentile, the ORs
for FPG were modestly attenuated but became larger for 1-
and 2-h plasma glucose. For both measures of neonatal
adiposity, there was a strong graded association across
increasing levels of maternal glycemia. In continuous
variable models for sum of skin folds 90th percentile,
ORs ranged from 1.37 to 1.52 in model I and 1.36 to 1.42 in
model II for each measure higher by 1 SD. In addition, for
percent body fat 90th percentile ORs ranged from 1.33 to
1.47 for model I and 1.35 to 1.44 for model II. There were
no signiﬁcant nonlinear associations for glucose or signif-
icant interactions with ﬁeld center, BMI, height, or MAP.
There was, however, a signiﬁcant interaction for 1-h
plasma glucose and age in relation to sum of skin folds
90th percentile, suggesting a stronger association of 1-h
plasma glucose with this outcome with increasing mater-
nal age.
Associations of glucose measures in continuous variable
models for fat-free mass 90th percentile showed similar
associations to those for percent fat 90th percentile,
with ORs in model II ranging from 1.30 to 1.44 (data not
shown). When birth weight, sum of skin folds, percent fat,
and fat free mass were modeled as continuous variables in
multiple regression analyses with adjustment for the same
confounders (model II), mean differences between the
highest and lowest categories for the glucose measures
ranged from 242 to 305 g for birth weight, 1.4 to 2.0 mm for
sum of skin folds, 1.5 to 2.5% for percent fat, and 157 to
168 g for fat free mass (all P  0.001).
Table 4 shows relationships between maternal glucose
and individual skin folds 90th percentile in continuous
variable analyses. Each individual skin fold measurement
was positively related to maternal glycemia. Strongest
associations were with subscapular skin fold where ORs
for each glucose measure higher by 1 SD ranged from 1.40
to 1.56 in model I and from 1.37 to 1.47 in model II. For
triceps skin fold, ORs ranged from 1.38 to 1.50 in model I
and from 1.38 to 1.40 in model II; whereas for ﬂank skin
fold, ORs ranged from 1.29 to 1.44 in model I and from 1.28
to 1.35 in model II. Associations did not vary signiﬁcantly
TABLE 3
Relationship between maternal glucose and percent body fat 90th percentile*
n 90th percentile† Model I Model II
FPG (mmol/l)
4.2 3,336 208 (6.2) 1.00 1.00
4.2–4.4 6,255 478 (7.6) 1.24 (1.05–1.47) 1.16 (0.98–1.38)
4.5–4.7 5,174 499 (9.6) 1.61 (1.36–1.90) 1.39 (1.17–1.65)
4.8–4.9 2,274 295 (13.0) 2.24 (1.86–2.70) 1.83 (1.51–2.21)
5.0–5.2 1,545 263 (17.0) 3.09 (2.54–3.74) 2.36 (1.92–2.89)
5.3–5.5 570 101 (17.7) 3.24 (2.51–4.19) 2.34 (1.79–3.05)
5.6 173 48 (27.7) 5.77 (4.02–8.29) 4.29 (2.95–6.24)
Continuous‡ 19,327 1,892 (9.8) 1.47 (1.41–1.54) 1.35 (1.28–1.42)
1-h Plasma glucose (mmol/l)
5.8 3,466 219 (6.3) 1.00 1.00
5.9–7.3 6,230 495 (7.9) 1.28 (1.09–1.51) 1.24 (1.05–1.47)
7.4–8.6 5,003 495 (9.9) 1.63 (1.38–1.92) 1.63 (1.37–1.93)
8.7–9.5 2,317 308 (13.3) 2.27 (1.89–2.73) 2.30 (1.91–2.78)
9.6–10.7 1,563 221 (14.1) 2.44 (2.00–2.97) 2.45 (1.99–3.02)
10.8–11.7 535 105 (19.6) 3.62 (2.81–4.66) 3.75 (2.87–4.88)
11.8 213 49 (23.0) 4.43 (3.13–6.27) 4.77 (3.33–6.83)
Continuous‡ 19,327 1,892 (9.8) 1.42 (1.35–1.48) 1.44 (1.37–1.52)
2-h Plasma glucose (mmol/l)
5.0 3,521 226 (6.4) 1.00 1.00
5.1–6.0 6,114 522 (8.5) 1.36 (1.16–1.60) 1.30 (1.10–1.53)
6.1–6.9 4,934 483 (9.8) 1.58 (1.34–1.86) 1.54 (1.30–1.83)
7.0–7.7 2,551 334 (13.1) 2.20 (1.84–2.62) 2.20 (1.83–2.64)
7.8–8.7 1,439 197 (13.7) 2.31 (1.89–2.83) 2.38 (1.93–2.93)
8.8–9.8 575 88 (15.3) 2.63 (2.02–3.43) 2.79 (2.13–3.68)
9.9 193 42 (21.8) 4.06 (2.81–5.86) 4.42 (3.03–6.47)
Continuous‡ 19,327 1,892 (9.8) 1.33 (1.27–1.39) 1.35 (1.29–1.42)
Data are n (%) or OR (95% CI). n 	 total number in the glucose category (excluding births with gestational age 30 weeks and fetal deaths).
Model I, adjusted for the variables used in estimating 90th percentiles; model II, adjusted for age, BMI, BMI
2, height, mean arterial blood
pressure, gestational age at the OGTT, smoking, alcohol use, hospitalization prior to delivery, and any family history of diabetes. *Deﬁned
based on sex, ethnicity, ﬁeld center, gestational age (36–44 weeks), and parity. †Number in the glucose category with percent body fat 90th
percentile (% proportion in the glucose category with percent body fat 90th percentile). ‡Glucose higher by 1 SD (0.4 mmol/l for FPG, 1.7
mmol/l for 1-h plasma glucose, 1.3 mmol/l for 2-h plasma glucose).
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outcomes. There was, however, a signiﬁcant interaction of
1-h plasma glucose with age in the model II analysis for
triceps skin fold, which suggested a stronger association
of 1-h plasma glucose with triceps skin fold with increas-
ing maternal age.
When model II ORs for birth weight 90th percentile,
percent body fat 90th percentile, or sum of skin folds
90th percentile associations with glucose as a continu-
ous variable were adjusted for C-peptide (using linear and
squared terms in C-peptide because of its nonlinear asso-
ciation with the outcomes) we found 23–38% reductions in
the ORs for associations with individual glucose measures
(data not shown).
Associations between categories of cord C-peptide and
neonatal anthropometrics are shown in Table 5. With
higher levels of cord C-peptide, frequency of each measure
of size and adiposity rose. For example, the frequency of
birth weight 90th percentile ranged from 4.5 to 25.6%
across categories of cord C-peptide. In model I, ORs for
the three measures ranged from 5.97 to 7.31 in the highest
category of cord C-peptide. In model II, ORs were mod-
estly attenuated, but strong graded associations remained.
When these outcomes and fat free mass were modeled
as continuous variables in multiple regression analyses
with adjustment for the same confounders (model II),
mean differences between the highest and lowest catego-
ries for cord C-peptide were 345 g for birth weight, 2.0 mm
for sum of skin folds, 2.7% for percent fat, and 221 g for fat
free mass (all P  0.001) (data not shown).
TABLE 4
Relationship* between maternal glucose and individual skin
folds 90th percentile†
Outcome Model I Model II
Flank skin fold 90th
percentile
FPG 1.44 (1.38–1.51) 1.34 (1.27–1.41)
1-h Plasma glucose 1.37 (1.31–1.44) 1.35 (1.28–1.42)
2-h Plasma glucose 1.29 (1.23–1.35) 1.28 (1.21–1.34)
Triceps skin fold 90th
percentile
FPG 1.50 (1.43–1.57) 1.40 (1.34–1.48)
1-h Plasma glucose 1.39 (1.33–1.46) 1.39 (1.32–1.46)
2-h Plasma glucose 1.38 (1.32–1.44) 1.38 (1.31–1.45)
Subscapular skin fold 90th
percentile
FPG 1.56 (1.49–1.64) 1.43 (1.36–1.51)
1-h Plasma glucose 1.50 (1.44–1.58) 1.47 (1.39–1.54)
2-h Plasma glucose 1.40 (1.34–1.46) 1.37 (1.30–1.43)
Data are OR (95% CI). Model I, adjusted for the variables used in
estimating 90th percentiles; model II, adjusted for ﬁeld center, age,
BMI, height, parity, smoking, alcohol use, hospitalization prior to
delivery, any family history of diabetes, mean arterial blood pressure,
and gestational age at OGTT. *Continuous variable analysis, glucose
higher by 1 SD (0.4 mmol/l for FPG, 1.7 mmol/l for 1-h plasma
glucose, and 1.3 mmol/l for 2-h plasma glucose). †Deﬁned based on
sex, ethnicity, ﬁeld center, gestational age (36–44 weeks only), and
parity.
TABLE 5
Relationship between cord serum C-peptide and neonatal anthropometrics
Cord serum C-peptide (g/l) n No. with outcome Model I Model II
Birth weight 90th percentile*
0.5 2,911 131 (4.5) 1.00 1.00
0.6–0.8 6,530 392 (6.0) 1.36 (1.11–1.66) 1.26 (1.03–1.55)
0.9–1.2 5,899 614 (10.4) 2.47 (2.03–2.99) 2.21 (1.82–2.70)
1.3–1.5 2,077 283 (13.6) 3.35 (2.70–4.15) 2.89 (2.32–3.60)
1.6–2.1 1,639 333 (20.3) 5.41 (4.37–6.69) 4.68 (3.77–5.82)
2.2–3.0 571 140 (24.5) 6.89 (5.32–8.93) 5.62 (4.31–7.33)
3.1 242 62 (25.6) 7.31 (5.21–10.25) 6.72 (4.75–9.51)
Total 19,869 1,955 (9.8)
Sum of skin folds 90th percentile*
0.5 2,412 117 (4.9) 1.00 1.00
0.6–0.8 5,647 369 (6.5) 1.37 (1.11–1.70) 1.27 (1.03–1.58)
0.9–1.2 5,145 513 (10.0) 2.17 (1.77–2.67) 1.92 (1.56–2.37)
1.3–1.5 1,821 267 (14.7) 3.37 (2.69–4.23) 2.84 (2.26–3.57)
1.6–2.1 1,409 265 (18.8) 4.54 (3.61–5.71) 3.74 (2.97–4.72)
2.2–3.0 485 101 (20.8) 5.16 (3.87–6.88) 4.00 (2.99–5.36)
3.1 181 46 (25.4) 6.68 (4.56–9.80) 5.57 (3.78–8.21)
Total 17,100 1,678 (9.8)
Percent body fat 90th percentile*
0.5 2,399 119 (5.0) 1.00 1.00
0.6–0.8 5,630 370 (6.6) 1.35 (1.09–1.67) 1.24 (1.00–1.54)
0.9–1.2 5,140 513 (10.0) 2.12 (1.73–2.61) 1.87 (1.52–2.31)
1.3–1.5 1,817 276 (15.2) 3.43 (2.74–4.30) 2.88 (2.30–3.62)
1.6–2.1 1,403 269 (19.2) 4.54 (3.62–5.70) 3.77 (2.99–4.75)
2.2–3.0 485 121 (25.2) 6.46 (4.90–8.51) 5.02 (3.79–6.66)
3.1 181 43 (23.8) 5.97 (4.05–8.81) 5.06 (3.41–7.52)
Total 17,050 1,726 (10.0)
Data are n (%) or OR (95% CI). n 	 total number in the cord C-peptide category (excluding births with gestational age 30 weeks and fetal
deaths); No. with outcome 	 number in the cord C-peptide category with the outcome (% proportion in the cord C-peptide category with the
outcome). Model I, adjusted for the variables used in estimating 90th percentiles; model II, adjusted for age, BMI, BMI
2, height, mean arterial
blood pressure, gestational age at the OGTT, smoking, alcohol use, hospitalization prior to delivery, and any family history of diabetes.
*Deﬁned based on sex, ethnicity, ﬁeld center, gestational age (36–44 weeks for skin folds and body fat), and parity.
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individual skin folds 90th percentile. Results for both
model I and model II show that subscapular skin fold has
the strongest and ﬂank skin fold the weakest association
with cord C-peptide level, with ORs for the highest versus
lowest category of 6.79 and 5.54 in models I and II,
respectively, for subscapular skin fold and 3.78 and 3.17
for ﬂank skin fold.
DISCUSSION
These results support our hypothesis that increasing glu-
cose concentration less severe than diabetes is associated
with fetal overgrowth, speciﬁcally adiposity. Data pre-
sented here show a strong and continuous association
between neonatal fat content and maternal glycemia and
with fetal insulin levels as measured by cord C-peptide
concentrations. These relationships were present for each
maternal glucose measurement and cord C-peptide. Rela-
tionships persisted even when potential confounding vari-
ables such as ﬁeld center, BMI, height, MAP, gestational
age, smoking status, and alcohol use were taken into
account. This pattern is similar to that reported for mater-
nal glucose and birth weight 90th percentile (2) and was
also seen for the association with fat free mass, a param-
eter derived by subtracting fat mass from total body
weight. Signiﬁcant interactions for 1-h plasma glucose and
age in relation to sum of skin folds 90th percentile and
triceps skin fold 90th percentile, which indicated stron-
ger associations with increasing age, may be a chance
ﬁnding due to the large number of interactions examined.
The ﬁndings reported here, however, are not proof of
causality. Fetal insulin, stimulated by maternal glucose
transport from mother to fetus across the placenta, may
act on a variety of nutrients in addition to glucose,
resulting in fetal overgrowth and adiposity. DiCianni et al.
(12) reported that maternal triglyceride levels were also
strongly correlated with fetal growth, a ﬁnding that is
consistent with the fuel mediated teratogenesis hypothesis
of Freinkel (13).
These ﬁndings conﬁrm the link between maternal gly-
cemia and neonatal fat deposition and suggest that the
relationship is mediated by fetal insulin production. Fur-
thermore, continuous relationships across the full range of
maternal glycemia suggest that the Pedersen hypothesis is
not limited to the high end of maternal glycemia but rather
describes a basic biological relationship that inﬂuences
maternal-fetal interactions around fetal growth. Each com-
ponent of the OGTT and level of cord C-peptide was
independently related to skin fold thickness with adjust-
ment for multiple potential confounders. On average,
maternal glucose was measured 11 weeks before collec-
tion of the cord blood serum C-peptide and measurements
of neonatal anthropometrics. Thus, it is not surprising that
associations of each glucose measure with anthropometric
outcomes were signiﬁcantly reduced but not eliminated
when adjusted for cord C-peptide. Correlations among the
glucose measures were modest (2), and an index of their
integrated associations with these anthropometric out-
comes is not available. No one glucose measurement was
clearly superior to the others, suggesting that ﬂuxes of
TABLE 6
Relationship between cord serum C-peptide and individual skin folds
Cord serum C-peptide (g/l) n No. with outcome Model I Model II
Flank skin fold 90th percentile*
0.5 2,421 135 (5.6) 1.00 1.00
0.6–0.8 5,664 374 (6.6) 1.20 (0.98–1.47) 1.12 (0.91–1.37)
0.9–1.2 5,167 496 (9.6) 1.80 (1.48–2.19) 1.61 (1.32–1.96)
1.3–1.5 1,826 267 (14.6) 2.90 (2.33–3.60) 2.48 (1.99–3.09)
1.6–2.1 1,413 227 (16.1) 3.24 (2.59–4.06) 2.70 (2.15–3.39)
2.2–3.0 487 98 (20.1) 4.27 (3.22–5.65) 3.39 (2.55–4.51)
3.1 181 33 (18.2) 3.78 (2.49–5.72) 3.17 (2.08–4.82)
Total 17,159 1,630 (9.5)
Triceps skin fold 90th percentile*
0.5 2,422 123 (5.1) 1.00 1.00
0.6–0.8 5,655 405 (7.2) 1.44 (1.17–1.77) 1.35 (1.10–1.66)
0.9–1.2 5,157 537 (10.4) 2.17 (1.77–2.66) 1.94 (1.58–2.38)
1.3–1.5 1,825 269 (14.7) 3.23 (2.59–4.04) 2.77 (2.21–3.47)
1.6–2.1 1,411 237 (16.8) 3.77 (3.00–4.74) 3.17 (2.51–3.99)
2.2–3.0 485 96 (19.8) 4.61 (3.46–6.15) 3.68 (2.75–4.93)
3.1 181 44 (24.3) 6.00 (4.08–8.82) 5.12 (3.47–7.56)
Total 17,136 1,711 (10.0)
Subscapular skin fold 90th percentile*
0.5 2,415 109 (4.5) 1.00 1.00
0.6–0.8 5,648 366 (6.5) 1.47 (1.18–1.83) 1.35 (1.09–1.69)
0.9–1.2 5,151 498 (9.7) 2.26 (1.83–2.80) 1.99 (1.60–2.47)
1.3–1.5 1,823 269 (14.8) 3.66 (2.90–4.62) 3.05 (2.41–3.86)
1.6–2.1 1,412 245 (17.4) 4.44 (3.51–5.63) 3.60 (2.83–4.58)
2.2–3.0 485 101 (20.8) 5.56 (4.16–7.45) 4.23 (3.14–5.69)
3.1 181 44 (24.3) 6.79 (4.60–10.03) 5.54 (3.73–8.23)
Total 17,115 1,632 (9.5)
Data are n (%) or OR (95% CI). n 	 total number in the cord C-peptide category (excluding births with gestational age 30 weeks and fetal
deaths), No. with outcome 	 number in the cord C-peptide category with the outcome (% proportion in the cord C-peptide category with the
outcome). Model I, adjusted for the variables used in estimating 90th percentiles; model II, adjusted for age, BMI, BMI
2, height, mean arterial
blood pressure, gestational age at the OGTT, smoking, alcohol use, hospitalization prior to delivery, and any family history of diabetes.
*Deﬁned based on sex, ethnicity, ﬁeld center, gestational age (36–44 weeks), and parity.
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state are related to fetal growth.
There is increasing evidence that increased size at birth
is associated with an increased likelihood of adiposity in
later life and with alterations in glucose metabolism and
-cell function (14). Increasing hyperglycemia in preg-
nancy, whether associated with high birth weight or not, is
associated with obesity and glucose intolerance later in
life (15). The ﬁnding of a continuous relationship between
maternal glycemia and neonatal adiposity offers the poten-
tial to better understand, and possibly to inﬂuence, the
development of obesity, a problem that is rapidly becom-
ing epidemic around the world (16). To date, published
studies of relationships between size at birth and risk of
obesity in childhood and later life (14) are based primarily
on birth weight for gestational age without information on
degree of adiposity at birth. Thus, follow-up studies of the
HAPO cohort or other populations that have information
on both maternal metabolic factors and obesity and neo-
natal body composition and insulin or C-peptide can be
very informative.
Limitations of the data include the fact that a cord
C-peptide level was not available for 15% of neonates.
Additionally, 14% of neonates who had a cord C-peptide
measurement did not have the full set of skin fold mea-
surements. Skin fold thickness is an indirect measure of
adiposity. However, the formula for calculation of body fat
that is based on baby length, weight, gestational age, and
ﬂank skin fold (11) was validated by measurements of
TOBEC, and the three skin fold measures are strongly
intercorrelated. Maternal body weight was only measured
at the time of the OGTT. Prepregnancy body weight was
self-reported and incomplete, and weight was not mea-
sured at delivery, making maternal weight gain unavailable
in a large number of cases. These limitations preclude our
ability to evaluate the differential effects of pre-existing
obesity and maternal weight gain in contributing to the
outcomes measured. However, there was a strong corre-
lation between recalled prepregnancy weight and weight
measured at the OGTT.
In summary, our data provide the “missing link” be-
tween maternal glycemia, fetal insulin response, and neo-
natal growth, speciﬁcally neonatal adiposity, conﬁrming
that the Pederson hypothesis ﬁrst proposed 50 years ago
(3) is not limited to overt diabetes, but extends across the
full range of maternal glycemia. The multicenter nature of
the cohort and the consistency of the results across
several measures of growth and adiposity make the results
particularly robust. The fact that the relationships extend
across the entire range of glycemia is also striking.
Whether the observed associations of the maternal meta-
bolic environment with fetal growth are indicative of
long-term effects on the increasing prevalence of obesity
and diabetes in both adolescents and adults remains to be
investigated.
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